Bridgebio Pharma
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
3160 Porter Dr Ste 250, Palo Alto, Calif...Phone Number
(650) 391-9740Website
www.bridgebio.comRevenue
$580 MillionStock Symbol
BBIOIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
6
7
1
2
2
2
About Bridgebio Pharma
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.Explore more
Bridgebio Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bridgebio Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Bridgebio Pharma is spiking on competitors!
Earning: See what the market has to say on Bridgebio Pharma recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Bridgebio Pharma
Bridgebio Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Bridgebio Pharma has recently received funding, and reach out quickly before it becomes old news!
Click to see if Bridgebio Pharma had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Bridgebio Pharma launches new products
Funding: Get notified immidiatlly once Bridgebio Pharma has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Bridgebio Pharma
Compare insights from companies similar to Bridgebio Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Bridgebio Pharma
$580M
501-1,000
Public
$2B
2015
JE
Julie EverettChief Operating Officer, Skeletal Dysplasias
Company Profile Activity
Activity Insights
Bridgebio Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Bridgebio Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Bridgebio Pharma.
Bridgebio Pharma financials insights
Gather financial insights about Bridgebio Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Multiple Rounds
$174.7M
2019
Other Financing Round
$299.2M
2020
Debt
$475M
2021
Debt
$750M
2025
Other Financing Round
$300M
Bridgebio Pharma Tech Stack
A closer look at the technologies used by Bridgebio Pharma
Most Recent Scoops
Hiring Plans
Bridgebio Pharma has more open roles in Finance than it has had at any time in the past 9 months. Areas of expertise include: Financial Risk, Treasury Operations, Cash Management, Bank Reconciliations, Trade Finance, Treasury Management, and Debt Management Planning.
Hiring Plans
Hiring Plans
Bridgebio Pharma has more open roles in Legal than it has had at any time in the past 12 months. Technologies mentioned include: Remote, BetterUp, and Spring Health. Areas of expertise include: Change Control, Regulatory Requirements, and Regulatory CMC.
Hiring Plans
Hiring Plans
Bridgebio Pharma has more open roles in Sales than it has had at any time in the past 12 months. Areas of expertise include: Sales Operations.
Hiring Plans
Open Position
Open Position
Bridgebio Pharma News & Media
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for treatment options for the LGMD2I/R9 communityCiti Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’t a Slam Dunk
BridgeBio Pharma (NASDAQ:BBIO) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company’s transthyretin amyloid cardiomyopathy (ATTR-CM) franchise. The call contrasts with Citi’s simultaneous Buy initiation Buy ratings on peer biotechs Alnylam, Ascendis Pharma, BioMarin, Cytokinetics, and of Ionis Pharmaceuticals (NASDAQ:IONS), making the BBIO Neutral a cautious outlier. For ... Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’tBridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript
BridgeBio Pharma, Inc. (BBIO) Bank of America Global Healthcare Conference 2026 May 12, 2026 5:20 PM EDTCompany ParticipantsThomas Trimarchi - CFO &...BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Bridgebio Pharma
Sign Up For FreeTo access detailed company insights
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial... Read More
